COMP <GO>
PAHC vs INVA // EV/EBITDA & P/E VALUATION
Phibro Animal Health Corporation (Class A) (NASDAQ) VS. Innoviva Inc. (NASDAQ) • 15-METRIC TALLY: PAHC 5
— INVA 5
▲ EV/EBITDA & P/E VALUATION LEADER: INVA
LAST: $38.86 (+2.59%) • MKT CAP: $1.58B
valuation
19.2x
LAST: $21.31 (+0.90%) • MKT CAP: $1.54B
valuation
7.6x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PAHC VS. INVA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PAHC | INVA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 30.90% | 74.80% | -43.90 | INVA | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 14.70% | -4.80 | INVA | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 19.2x | 7.6x | +11.60 | INVA | /valuation <GO> |
| Free Cash Flow Yield | 5.08% | 12.72% | -7.64 | INVA | /fcf-yield <GO> |
| Operating Margin | 8.50% | 39.80% | -31.30 | INVA | /operating-margins <GO> |
| Net Profit Margin | 3.70% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 27.40% | 14.70% | +12.70 | PAHC | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 1.23% | 0.00% | +1.23 | PAHC | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.87 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 6/9 | +2.00 | PAHC | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 56.9 | 53.4 | +3.50 | PAHC | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.5x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.58B | $1.54B | $38.2M | PAHC | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PAHC REV | INVA REV | PAHC GROSS % | INVA GROSS % | PAHC FCF | INVA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.30B | $411.3M | 30.9% | 74.8% | $80.1M | $195.8M |
| FY 2024 | $1.02B | $358.7M | 30.8% | 82.6% | $87.6M | $188.4M |
| FY 2023 | $977.9M | $310.5M | — | — | $13.3M | $141.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PAHC // BETA —
INVA // BETA —